Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Therapy vs Etanercept vs MTX for RA Relapse Prevention (ESCoRT)
NCT02320630Phase 4Unknown
- Sponsor
- Peking University First Hospital
- Start
- Oct 2015
- Primary completion
- Feb 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of hydroxychloroquine, 5-aminosalicylic acid + sulphasalazine, methotrexate in rheumatoid arthritis (RA), sponsored by Peking University First Hospital. Status: unknown.
02
Drugs
hydroxychloroquine5-aminosalicylic acid + sulphasalazinemethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02320630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02320630.